Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$274.26 USD

274.26
329,299

+2.04 (0.75%)

Updated May 17, 2024 04:00 PM ET

After-Market: $274.40 +0.14 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

3D Systems (DDD) Report Preliminary 3Q Results, Scrap 2023 View

3D Systems (DDD) expects to report dismal third-quarter 2023 results due to softness in printer demand.

ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease

The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.

3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity

3D Systems' (DDD) collaboration with Klarity is likely to help it in expanding the distribution of its FDA-approved VSP Bolus solution.

Should You Invest in the Invesco Biotechnology & Genome (PBE)?

Sector ETF report for PBE

Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 18.82% and 12.06%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Esperion Therapeutics (ESPR) Down 6.9% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

United Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line.

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q1 Earnings

The headline numbers for United Therapeutics (UTHR) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

United Therapeutics (UTHR) Q1 Earnings Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 11.72% and 1.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More

Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Relay Therapeutics, Inc. (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is iShares US SmallCap Equity Fac (SMLF) a Strong ETF Right Now?

Smart Beta ETF report for SMLF

United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates

United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.

United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?